Andrographis EP80 (Andrographis paniculata)

Andrographis EP80 is a standardized extract of Andrographis paniculata containing 80% andrographolides, diterpene lactones with potent immunomodulatory and anti-inflammatory properties. Clinical research demonstrates its efficacy for respiratory infection recovery and COVID-19 symptom management through NF-κB pathway inhibition.

Origin & History

Andrographis paniculata is a herbaceous plant native to South Asia, particularly India and Sri Lanka, belonging to the Acanthaceae family. The ingredient is typically derived through extraction of the plant's aerial parts, with standardized extracts commonly containing andrographolide as the primary active compound, often standardized to specific concentrations (e.g., 20 mg andrographolide per capsule).

Historical & Cultural Context

While the research dossier does not provide detailed information on traditional use, Andrographis paniculata has been utilized in South Asian medicine systems. The plant's standardization into modern extracts like EP80 represents the evolution from traditional herbalism to evidence-based supplementation.

Health Benefits

• Supports recovery from mild-to-moderate COVID-19 based on a 2024 meta-analysis of 6 RCTs (n=660) showing improved clinical recovery and reduced inflammatory markers
• Reduces upper respiratory tract infection symptoms with demonstrated efficacy for sore throat (OR=2.3, 95% CI 1.69-3.14) and other cold symptoms
• Enhances immune function in HIV-positive patients, increasing CD4+ lymphocyte counts from 405 to 501 cells/mm³ in a Phase I clinical trial
• Provides anti-inflammatory effects through NF-κB suppression and inhibition of inflammatory cytokines based on mechanistic studies
• Exhibits antiplatelet activity through multiple pathways including eNOS-NO/cyclic GMP activation, suggesting cardiovascular protective effects

How It Works

Andrographolides inhibit nuclear factor kappa-B (NF-κB) signaling pathways, reducing pro-inflammatory cytokine production including TNF-α, IL-1β, and IL-6. The compounds also modulate T-helper cell differentiation, promoting Th1 immune responses while suppressing excessive Th2 activation. Additionally, andrographolides demonstrate direct antiviral activity by interfering with viral replication mechanisms.

Scientific Research

A 2024 systematic review and meta-analysis evaluated six randomized controlled trials involving 660 adults with mild-to-moderate COVID-19, with one trial (Wanaratna et al., 2022) administering 180 mg andrographolide daily for 5 days. Clinical studies demonstrated prophylactic and therapeutic benefits for upper respiratory tract infections, while a Phase I trial in HIV-positive patients showed significant improvement in CD4+ lymphocyte counts using a dose escalation protocol up to 20 mg/kg body weight.

Clinical Summary

A 2024 meta-analysis of 6 randomized controlled trials (n=660) showed Andrographis significantly improved COVID-19 clinical recovery and reduced inflammatory markers compared to placebo. For upper respiratory tract infections, clinical trials demonstrate efficacy with odds ratios of 2.3 (95% CI 1.69-3.14) for sore throat relief. Most studies used standardized extracts containing 80-95% andrographolides at doses of 60-120mg daily. The evidence quality is moderate, with studies showing consistent benefits across different respiratory conditions.

Nutritional Profile

Andrographis EP80 is a standardized herbal extract, not a conventional food ingredient, so traditional macronutrient profiling is largely not applicable; however, its bioactive composition is well-characterized. The EP80 designation indicates standardization to a minimum of 80 mg/g (8%) andrographolide content per gram of extract. Primary bioactive compounds include: andrographolide (major diterpene lactone, typically 8–30% depending on extraction batch, with EP80 standardized to ≥8%), 14-deoxyandrographolide, neoandrographolide, and 14-deoxy-11,12-didehydroandrographolide. Secondary bioactives include arabinogalactan polysaccharides and flavonoids (apigenin, luteolin, wogonin derivatives). Andrographolide has documented poor oral bioavailability (~20–30%) due to first-pass metabolism and low aqueous solubility, though standardized extracts and EP80 formulations are designed to optimize consistency of delivery. The extract is essentially devoid of meaningful macronutrient content (negligible protein, fat, and carbohydrate at typical supplemental doses of 200–400 mg). Mineral and vitamin content is trace and clinically insignificant. The primary pharmacological activity is driven by andrographolide's NF-κB inhibition and Nrf2 pathway modulation. Typical therapeutic doses used in RCTs range from 180 mg to 1200 mg of standardized extract daily.

Preparation & Dosage

Standardized extract dosages vary by condition: COVID-19 (180 mg andrographolide daily for 5 days), HIV support (1,500-2,000 mg andrographolide daily for 6 weeks or dose escalation from 5-20 mg/kg body weight), and general immune support (4-20 mg andrographolide per dose unit). Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Eleutherococcus senticosus, Schizandra chinensis, Glycyrrhiza glabra, Vitamin C, Zinc

Safety & Interactions

Andrographis EP80 is generally well-tolerated with mild gastrointestinal side effects reported in 5-10% of users, including nausea and loose stools. It may enhance anticoagulant effects of warfarin and increase bleeding risk when combined with antiplatelet medications. Theoretical interactions exist with immunosuppressive drugs due to immune-stimulating properties. Pregnancy and breastfeeding safety data are insufficient, warranting avoidance during these periods.